Technology area: Biotechnology & Pharmaceuticals
6 pending office actions • 5 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 8 patents granted in the last 365 days
CRISPR Therapeutics AG has 6 pending office actions in Biotechnology & Pharmaceuticals. The matters are assigned to 6 examiners across 5 art units, indicating broad examiner distribution with some art-unit overlap.
POPA, ILEANA is the busiest examiner with 1 pending matter. A common review of biotechnology terminology and claim themes can support consistency, but each response should account for the individual examiner and assigned art-unit context.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (17%) |
| Double-patenting + other | 1 (17%) |
| Multi-statute (no §101) | 2 (33%) |
| No statute on record | 2 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| POPA, ILEANA | 1 | 21.7% | +15.7% |
| FAUST, AMBER KATHLEEN | 1 | 61.1% | +53.6% |
| YU, DELPHINUS DOU YI | 1 | 33.3% | +0.0% |
| OGUNBIYI, OLUWATOSIN A | 1 | 63.8% | +41.2% |
| LEONARD, ARTHUR S | 1 | 50.5% | +50.4% |
| VIJAYARAGHAVAN, JAGAMYA NMN | 1 | 61.0% | +51.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17906471 | T-CELL BISPECIFIC BINDING PROTEINS | OGUNBIYI, OLUWATOSIN A | 126d overdue |
| 19010148 | MATERIALS AND METHODS FOR TREATMENT OF HEREDITARY HAEMOCHROMATOSIS | POPA, ILEANA | — |
| 18336961 | LIPID NANOPARTICLES (LNPs)-BASED OCULAR DELIVERY | YU, DELPHINUS DOU YI | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17906471 | T-CELL BISPECIFIC BINDING PROTEINS | OGUNBIYI, OLUWATOSIN A | 126d overdue |
| 17491761 | MATERIALS AND METHODS FOR ENGINEERING CELLS AND USES THEREOF IN IMMUNO-ONCOLOGY | VIJAYARAGHAVAN, JAGAMYA NMN | 80d overdue |
| 19010148 | MATERIALS AND METHODS FOR TREATMENT OF HEREDITARY HAEMOCHROMATOSIS | POPA, ILEANA | — |
| 18482752 | GENETICALLY ENGINEERED ANTI-CD19 CAR-T CELLS FOR USE IN TREATING B-CELL MALIGNANCIES | FAUST, AMBER KATHLEEN | — |
| 17818673 | UNIVERSAL DONOR CELLS | LEONARD, ARTHUR S | — |
| Art Unit | Apps |
|---|---|
| 1633 | 2 |
| 1643 | 1 |
| 1636 | 1 |
| 1645 | 1 |
| 1631 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19010148 | MATERIALS AND METHODS FOR TREATMENT OF HEREDITARY HAEMOCHROMATOSIS | POPA, ILEANA | 1633 | Other | Non-Final OA | — | Pending | Jan 05, 2025 |
| 18482752 | GENETICALLY ENGINEERED ANTI-CD19 CAR-T CELLS FOR USE IN TREATING B-CELL MALIGNANCIES | FAUST, AMBER KATHLEEN | 1643 | §103§112DP | Non-Final OA | — | Pending | Oct 06, 2023 |
| 18336961 | LIPID NANOPARTICLES (LNPs)-BASED OCULAR DELIVERY | YU, DELPHINUS DOU YI | 1636 | §103§112Other | Non-Final OA | — | Pending | Jun 17, 2023 |
| 17906471 | T-CELL BISPECIFIC BINDING PROTEINS | OGUNBIYI, OLUWATOSIN A | 1645 | §103§112 | Non-Final OA | 126d overdue | Pending | Sep 15, 2022 |
| 17818673 | UNIVERSAL DONOR CELLS | LEONARD, ARTHUR S | 1631 | Other | Final Rejection | — | Pending | Aug 09, 2022 |
| 17491761 | MATERIALS AND METHODS FOR ENGINEERING CELLS AND USES THEREOF IN IMMUNO-ONCOLOGY | VIJAYARAGHAVAN, JAGAMYA NMN | 1633 | §103Other | Non-Final OA | 80d overdue | Pending | Oct 01, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCRISPR Therapeutics AG has 6 pending office actions as of October 2026, spread across 5 art units and 6 examiners.
Ileana Popa has the most, with 1 of CRISPR Therapeutics AG's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
